ITALY- February 19, 2019
Carlo Giaquinto, MD
Department of Paediatrics at the University of Padova,
Carlo Giaquinto is head of several organisations including, Head of the Referral Centre for Paediatric HIV infection at the Department of Paediatrics of the University of Padua since 1993, Head of the Paediatric European network treatment AIDS (PENTA network) since 1994 and co-chair of the EU funded Network of Excellence TEDDY (Task Force in Europe for Drug Development in the Young). He is also president of the PENTA foundation and chairman of the Paediatric Rotavirus European Committee (PROTECT) group. He is also the chair of the GRIP project (Global Research in Pediatrics) an EU funded network of Excellence.
Dr. Giaquinto is coordinator for various projects including the social AIDS projects financed by the European Community and by other international organisations both in Europe and Africa. He is coordinator of Pedianet: a primary care paediatric database. He has served as honorary senior lecturer in the centre for paediatric epidemiology and biostatistics of the Institute of Child Health in London since 2002.
He is Author of more than 180 publications in peer-reviewed journals and has been invited as speaker at more than 300 conferences and international workshops across the world.
FRANCE - March 13, 2019
Nicholas Moore, MD, PhD, FRCP (Edin)
FISPE, Honorary Member ISOP, Chevalier dans l'ordre National des Palmes Académiques Nicholas Moore is Head of the department of Pharmacology in Bordeaux,
a 100+ strong department with teams working in experimental pharmacology, therapeutic drug monitoring and toxicology, in pharmacovigilance and pharmacoepidemiology (an ENCEPP centre), in clinical pharmacology.
He is head of the Clinical Investigation Centre, in Bordeaux for interventional and observational research. Nicholas Moore was born in New York, USA in 1953, and has dual French-US citizenship. He did his medical studies in Paris then trained in cardiology and pharmacology in Rouen. He spent dozen years more in Rouen in Clinical Pharmacology and Pharmacovigilance, during which time he became vice-president of the French Association of Regional Pharmacovigilance Centres, and founded the European Society of Pharmacovigilance. He moved to Bordeaux in 1996 as Professor of Clinical Pharmacology.
He was Coordinator of Clinical Research for the university hospital in Bordeaux and for the South-west and Overseas region of France (2003-2011). He was president of ISOP, the International Society of Pharmacovigilance, from 2006 to 2009, Vice-Chairman of the European Association of Clinical Pharmacology and Therapeutics from 2003 to 2011, Director of the International Society of Pharmacoepidemiology (ISPE) from 2003 to 2011, and is a member of the ENCEPP Steering Committee.
He has co-authored over 400 papers in peer-reviewed journals.
UK - April 25,2019
Thomas MacDonald, BSC, MBCHB, MD
Professor of Clinical Pharmacology & Pharmacoepidemiology in the Medical Research Institute, University of Dundee, and Honorary Consultant Physician at Ninewells Hospital and Medical School.
His research interests are hypertension, cardiovascular disease, pharmacoepidemiology and drug safety and innovative trial designs. He is the immediate past president of the British Hypertension Society, a past president of the International Society of Pharmacoepidemiology and the current director of the Tayside Medicines Monitoring Unit (MEMO) which has access to the MEMO database and to the CPRD database. He is an elected member of the steering committee of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
Professor MacDonald has published extensively on drug safety especially the safety of non-steroidal anti-inflammatory drugs (NSAIDs). He has also published many studies of hypertension and other cardiovascular risk factors and cardiovascular disorders.
GERMANY - May (date tbc), 2019
Dr Niklas Schmedt, BSC, MBCHB, MD
Head of Health Services Research & Pharmacoepidemiology, InGef – Institute for Applied Health Research Berlin.
Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending.
Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending. Bios pending.
NORDIC COUNTRIES - June (date tbc), 2019
Vera Ehrenstein, MPH, DSc
Professor at the Department of Clinical Epidemiology Aarhus University, Denmark, responsible for post marketing studies.
Vera Ehrenstein coordinates several international pharmacoepidemiology, pharmacovigilance and clinical epidemiology studies in collaboration with industry or regulators. She is a member of the ENCePP Steering Committee and serves as the 2016-2017 Chair of the Academic Council at the International Society of Pharmacoepidemiology. She earned a doctorate in epidemiology in 2008, and an MPH in epidemiology and biostatistics in 2000, from Boston University.
Vera Ehrenstein has co-authored a book chapter and published about 80 peer-reviewed papers within the fields of clinical epidemiology, pharmacoepidemiology and fetal origins of adult disease.
Edeltraut Garbe, MSC
Board-certified specialist in Internal Medicine (1990) and Clinical Pharmacology (1998) with a “Habilitation” in Clinical Pharmacology (2000, Charité University Hospital Berlin). Prof. Garbe holds a Master of Science degree in Epidemiology and Biostatistics from McGill University, Montreal (1997), where she is part-time Adjunct Professor in the Department of Medicine, Division of Clinical Epidemiology.
After her residentship in Internal Medicine at the Central Hospital "Links der Weser" in Bremen she worked from 1990-1997 as Scientific Director in the Department of Experimental and Clinical Pharmacology at the Federal Institute for Drugs and Medical Devices (BfArM). In 1997 she became Director of the Potsdam Institute of Pharmacoepidemiology and Technology Assessment and in 2002, Associate Professor of Clinical Pharmacology at the Charité University Hospital in Berlin. During her time at Charité, she established the Berlin Case-Control Surveillance of rare, serious adverse drug reactions. 2007-2015 she has been Full Professor of Clinical Epidemiology at the University of Bremen and Head of the Department of Clinical Epidemiology at the now-called Leibniz Institute for Prevention Research and Epidemiology - BIPS. Her scientific focus is on drug utilization and drug safety studies making use of large healthcare databases or field-based settings. She and her co-workers have established the first large pharmaco-epidemiological database for Germany.
Prof. Garbe is chairperson/member of several scientific advisory boards of post-authorization safety studies, chairperson of one ethic committee in Berlin, member of the Standing Vaccination Committee in Germany, member of the scientific advisory board of the German Federal Insurance Office for the morbidity-oriented risk structure compensation of health insurances in Germany and deputy member of the Expert Advisory Committee for Prescription-Only Issues at the Federal Institute for Drugs and Medical Devices in Germany.
SPAIN- July (date tbc), 2019
Speaker to be confirmed
Esther is a pharmaco-epidemiologist and fully qualified pharmacist with experience in community and hospital pharmacies in Spain and the UK. Esther holds a postgraduate diploma in Biomedical Sciences and Scientific English from King´s College London, an MSc in Clinical Research and Medical Affairs from Ephos School of PharmaStudies, and an MSc in Pharmacoepidemiology and Pharmacovigilance from the Eu2P.
She has been involved in numerous projects in the field of risk minimisation, and in several research initiatives including a review of aRMMs identified in the European Public Assessment Reports and a quantitative review of survey studies assessing the effectiveness of risk minimisation measures in the EUPAS.
Multi-country field studies - July (date tbc), 2019
Ana Filipa Maceda, PharmD PhD
Director of Epidemiology at OXON
Ana Filipa Macedo holds a Pharmaceutical degree and a PhD in Pharmacoepidemiology. She has more than 17 years of experience in the design and conduct of studies using primary data collection and secondary data sources. She has worked across various therapeutic areas, in the design of observational studies on the natural history of disease and comparative safety and effectiveness of medical treatments.
Ana Filipa was a research fellow at the London School of Hygiene and Tropical Medicine, where she worked with Prof. Liam Smeeth and Ian Douglas in studies using CPRD; and joined the Cochrane Heart group, working with Prof. Shah Ebrahim in the conduct of numerous systematic reviews and meta-analyses. Ana Filipa also worked in the Pharmaceutical Industry in the UK, being responsible for the evidence synthesis required for health technology appraisals, including network meta-analyses. She is co-author of the book chapter “Primary data collection for Pharmacoepidemiology” in Brian Strom’s textbook “Pharmacoepidemiology”. 20018 (In Press).
Professor of Epidemiology and Health Services Research at University of Ulster since 2000. She is Head of the Centre for Maternal, Fetal and Infant Research within the Institute for Nursing Research, University of Ulster.
After graduating from the University of Oxford, where she studied zoology, Helen Dolk spent several years in behavioural ecology research before moving to a research fellow position at the University of Louvain, Belgium where she gained her Doctorate in Public Health (Epidemiology) in 1990. From 1991 to 1999 she was Lecturer and Senior Lecturer in Environmental Epidemiology at the London School of Hygiene and Tropical Medicine.
Her research interests are perinatal and environmental epidemiology, epidemiologic surveillance, use of disease registries and healthcare databases, primary prevention of congenital anomalies, pharmacovigilance related to medication use in pregnancy, socioeconomic inequalities in perinatal health, and effects of environmental pollutants on perinatal health.
Current Research Projects are: EUROCAT: European Surveillance of Congenital Anomalies. EU DG Sanco Public Health Programme. (Project Leader/Director), EUROmediCAT: Safety of medication use in pregnancy in relation to risk of congenital malformations. EU Framework 7. (PI), Northern Ireland Baby Hearts Study. Chest, Heart and Stroke. (PI), Administrative Data Research Centre NI (co-I).
Lorenzo Domínguez, MD, MPH
Director of Operations at OXON, Madrid.
Lorenzo is a medical doctor and epidemiologist with more than 20 years of experience in conducting observational studies in all major therapeutic areas in southern Europe.
Lorenzo previously worked as an epidemiologist at AstraZeneca and the global CRO, SGS.
Miriam Sturkenboom, PhD, PharmD
Professor in Observational Data Analysis at the department of Medical Informatics of the Erasmus University Medical Center in the Netherlands.
She has a PhD from the Faculty of Mathematics and Physics in Groningen (cum laude), a pharmacy degree and a Master in Epidemiology from the Harvard School of Public Health.
Her research group focuses on knowledge discovery from data collected in routine health care to improve evidence on drug and vaccine safety and rare diseases. Her group has created national and most importantly international socio-technological infrastructures that allow for big data mining, pooling and analysis. These infrastructures have been tested and used as prototypes in many distributed networks in projects funded by the European Commission (SOS, ARITMO, SAFEGUARD, GRIP), the Innovative Medicines Initiative (ADVANCE), the European Medicines Agency, ECDC (VAESCO), CDC (SOMNIA), WHO (GVS-MCC) as well as in privately funded projects. She is past-president of the International Society of Pharmacoepidemiology, president of VACCINE.GRID and has more than 400 peer reviewed papers in pharmacovigilance, pharmacoepidemiology and medical informatics.
Nawab Qizilbash, MBChB MRCP (UK) BSc MSc DPhil (Oxon.)
Nawab Qizilbash is Clinical Epidemiologist & Head of OXON Epidemiology, Joint Coordinator of the ENCePP Special Interest Group on Impact of PV Activities and:
- Honorary Senior Lecturer in Epidemiology, London School of Hygiene and Tropical Medicine, London University
- Honorary Consultant Geriatrician, Hospital Cantoblanco, Madrid
- Member of Green Templeton College, Oxford University
- Co-author of x7 Lancet, x1 JAMA and x3 BMJ publications in epidemiology, pragmatic trials and meta-analysis
- Chief editor of 'Evidence-based Dementia Practice' published by Blackwells, Oxford.
Former Nawab was Director of Epidemiology and Evidence-based Medicine, GSK (1997-2005); he trained under and worked with Professor Sir Richard Peto F.R.S., and was founding editor of the Cochrane Dementia Group. He also trained in general internal medicine and geriatrics under Professor Sir John Grimley Evans and was Honorary Consultant Physician at the Radcliffe Infirmary, Oxford (1997-2000), and St's Mary's Hospital, London (2005-2006).
Among CROs in Europe, Nawab provides clients with a unique combination of high quality epidemiological and clinical experience covering many therapeutic areas.
Ulf Bergman MD, Ph.D., FISPE, FRCP (Edin)
Professor Emeritus, Division of Clinical Pharmacology and Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
As former Medical Officer at the hospital he provided service, teaching and research in the areas of clinical pharmacology, drug utilization research /pharmacoepidemiology, rational use of drugs and quality indicators, adverse drug reaction evaluations and drug abuse. He was a temporary advisor to WHO, founding member of the European Drug Utilization Research Group (EuroDURG) and the International Society for Pharmacoepidemiology – ISPE.
Currently he is member of the EMAs European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). He is also a Senior Advisor at the Center for International Organizations of Medical Sciences (CIOMS) in Geneva. He has published some 200 peer-reviewed papers and co-authored many books.